Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP -0.25%58 OCF Yield % is 6.12 as of Aug. 10, 2026, which is 787% above its 10-year median of 0.69. GuruFocus rates ELTP with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 66.27% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Elite Pharmaceuticals OCF Yield % Related Terms
Elite Pharmaceuticals OCF Yield % Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals (ELTP) has a OCF Yield % of 6.12 as of Aug. 10, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Elite Pharmaceuticals and its competitors. This is 787% above median its historical median of 0.69. According to the industry distribution chart, Elite Pharmaceuticals ranks #339 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 33.7%.
Is Elite Pharmaceuticals' OCF Yield % too high?
Elite Pharmaceuticals' current OCF Yield % of 6.12 is 787% above median its 10-year median of 0.69. The Drug Manufacturers industry median OCF Yield % is 3.46. Elite Pharmaceuticals' value of 6.12 is 76.9% above this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #339 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Elite Pharmaceuticals has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' OCF Yield % compare to EOLS and EBS?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #339 out of 1005 companies for OCF Yield %. This puts Elite Pharmaceuticals in the upper half of its industry. The industry median OCF Yield % is 3.46. Elite Pharmaceuticals' value of 6.12 is 76.9% above this benchmark. While the company's 10-year median is 0.69 vs. the industry median of 3.46, Elite Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.46, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current OCF Yield % of 6.12 is 76.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current OCF Yield % is 6.12, which is 787% above median its own 10-year median of 0.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.36 — trading 36.8% below its estimated fair value. The current OCF Yield % is 6.12, which is 787% above median its 10-year median of 0.69 and 76.9% above the Drug Manufacturers industry median of 3.46. Elite Pharmaceuticals' overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current OCF Yield % is 6.12 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.36 is trading 36.8% below its estimated GF Value™ of $0.57.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
OCF Yield %: 6.12 (787% above median its 10-year median of 0.69)
GF Value™: $0.57 vs. price of $0.36 (36.8% below fair value)
Industry Position: 76.9% above the Drug Manufacturers median (#339 of 1005)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
58GF Score
Get the complete analysis for ELTP
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
